Omega Diagnostics (GB:CNSL) has released an update.
Cambridge Nutritional Sciences PLC reports robust financial performance for the fiscal year 2024, with a 30% increase in revenue to £9.8m and a significant jump in gross profit margin to 62%, up from 47% the previous year. The company anticipates a positive adjusted EBITDA, in contrast to a £2.0m loss in 2023, and enters FY25 with a strong order book and a focus on growth in the UK and digital expansion in India. Alongside these financial gains, the company announces a directorate change with Carolyn Rand taking over as Chair from Dr Simon Douglas.
For further insights into GB:CNSL stock, check out TipRanks’ Stock Analysis page.
